Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apricus Biosc Inc (APRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 17,381
  • Shares Outstanding, K 12,780
  • Annual Sales, $ 5,760 K
  • Annual Income, $ -7,430 K
  • 36-Month Beta 0.57
  • Price/Sales 2.99
  • Price/Cash Flow 0.00
  • Price/Book 2.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.03 +36.89%
on 07/19/17
1.45 -2.76%
on 08/02/17
+0.36 (+34.29%)
since 07/17/17
3-Month
0.86 +63.95%
on 05/25/17
1.45 -2.76%
on 08/02/17
+0.38 (+36.89%)
since 05/17/17
52-Week
0.86 +63.95%
on 05/25/17
4.90 -71.22%
on 09/15/16
-1.59 (-53.00%)
since 08/17/16

Most Recent Stories

More News
Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma

If you want a Stock Review on DRRX, SCMP, APRI, or MEIP then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The profitability of individual companies...

DRRX : 1.70 (+1.19%)
SCMP : 10.35 (+0.97%)
APRI : 1.41 (+3.68%)
MEIP : 2.77 (+0.36%)
Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results

Vitaros Drug-Device Human Factor Studies Successfully Completed

APRI : 1.41 (+3.68%)
Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results

Vitaros Drug-Device Human Factor Studies Successfully Completed

APRI : 1.41 (+3.68%)
Investor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 2, 2017 / APRICUS BIOSCIENCES, INC. (NASDAQ: APRI) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 2, 2017 at 4:30...

APRI : 1.41 (+3.68%)
Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' second quarter 2017 financial results will...

APRI : 1.41 (+3.68%)
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results

Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017

APRI : 1.41 (+3.68%)
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results

Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017

APRI : 1.41 (+3.68%)
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that the Vitaros...

APRI : 1.41 (+3.68%)
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' first quarter 2017 financial results will...

APRI : 1.41 (+3.68%)
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus'...

APRI : 1.41 (+3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the...

See More

Support & Resistance

2nd Resistance Point 1.42
1st Resistance Point 1.39
Last Price 1.41
1st Support Level 1.32
2nd Support Level 1.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.